Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin is highly expressed in many tumor types and has reported prognostic value. To generate tumor-specific immune response, a novel cancer vaccine was formulated in DepoVax platform (DPX-Survivac) using survivin HLA class I pep...

Descripción completa

Detalles Bibliográficos
Autores principales: Berinstein, Neil L, Karkada, Mohan, Oza, Amit M, Odunsi, Kunle, Villella, Jeannine A, Nemunaitis, John J, Morse, Michael A, Pejovic, Tanja, Bentley, James, Buyse, Marc, Nigam, Rita, Weir, Genevieve M, MacDonald, Lisa D, Quinton, Tara, Rajagopalan, Rajkannan, Sharp, Kendall, Penwell, Andrea, Sammatur, Leeladhar, Burzykowski, Tomasz, Stanford, Marianne M, Mansour, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
MIATA Compliant Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570133/
https://www.ncbi.nlm.nih.gov/pubmed/26405584
http://dx.doi.org/10.1080/2162402X.2015.1026529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570133/
https://www.ncbi.nlm.nih.gov/pubmed/26405584
http://dx.doi.org/10.1080/2162402X.2015.1026529

Ejemplares similares